Expression of FRA16D/WWOX and FRA3B/FHIT Genes in Hematopoietic Malignancies

Molecular Cancer Research

Volumn 1, Issue 13, 2003, Pages 940-947

  Ishii, Hideshi ^a,c   Vecchione, Andrea ^c   Furukawa, Yutaka ^a   Sutheesophon, Krittaya ^a   Han, Shuang Yin ^c   Druck, Teresa ^c   Kuroki, Tamotsu ^c   Trapasso, Francesco ^c   Nishimura, Miki ^b   Saito, Yasushi ^b   Ozawa, Keiya ^a   Croce, Carlo M ^c   Huebner, Kay ^c   Furukawa, Yusuke ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FRAGILE HISTIDINE TRIAD PROTEIN; HISTONE; MESSENGER RNA; NUCLEOTIDE; OXIDOREDUCTASE;

ACETYLATION; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMETHYLATION; EMBRYO; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; WILD TYPE;

ACETYLATION; ACID ANHYDRIDE HYDROLASES; BASE SEQUENCE; CELL LINE; CELL LINE, TUMOR; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HL-60 CELLS; HUMANS; IMMUNOBLOTTING; JURKAT CELLS; K562 CELLS; MUTATION; NEOPLASM PROTEINS; OXIDOREDUCTASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; U937 CELLS;

EID: 0344874589     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Yunis, J. J. and Soreng, A. L. Constitutive fragile sites and cancer. Science, 226, 1199-1204, 1984.
2. Glover, T. W., Berger, C., Coyle, J., and Echo, B. DNA polymerase α. inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum. Genet., 67: 136-142, 1984.
3. Arlt, M. F., Miller, D. E., Beer, D. G., and Glover, T. W. Molecular charactenzation of FRAXB and comparative common fragile site instability in cancer cells. Genes Chromosomes & Cancer, 33: 82-92, 2002.
4. Ohta, M., Inoue, H., Cotticelli, M. G., Kastury, K., Baffa, R., Palazzo, J., Siprashvili, Z., Mori, M., McCue, P., Druck, T., Croce, C. M., and Huebner, K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell, 84: 587-597, 1996.
5. Sozzi, G., Huebner, K., and Croce, C. M. FHIT in human cancer. Adv. Cancer Res., 74: 141-166, 1998.
6. Ishii, H., Dumon, K. R., Vecchione, A., Fong, L. Y., Baffa, R., Huebner, K., and Croce, C. M. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies. JAMA, 286: 2441-2449, 2001.
7. Zochbauer-Muller, S., Fong, K. M., Maitra, A., Lam, S., Geradts, J., Ashfaq, R., Virmani, A. K., Milchgrub, S., Gazdar, A. F., and Minna, J. D. 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res., 61: 3581-3585, 2001.
8. Tanaka, H., Shimada, Y., Harada, H., Shinoda, M., Hatooka, S., Imamura, M., and Ishizaki, K. Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res., 58: 3429-3434, 1998.
9. Trapasso, F., Krakowiak, A., Cesari, R., Arkles, J., Yendamuri, S., Ishii, H., Vecchione, A., Kuroki, T., Bieganowski, P., Pace, H. C., Huebner, K., Croce, C. M., and Brenner, C. Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding. Proc. Natl. Acad. Sci. USA, 100: 1592-1597, 2003.
10. Bednarek, A. K., Laflin, K. J., Daniel, R. L., Liao, Q., Hawkins, K. A., and Aldaz, C. M. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res., 60: 2140-2145, 2000.
11. Paige, A. J., Taylor, K. J., Taylor, C., Hillier, S. G., Farrington, S., Scott, D., Porteous, D. J., Smyth, J. F., Gabra, H., and Watson, J. E. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc. Natl. Acad. Sci. USA, 98: 11417-11422, 2001.
12. Kuroki, T., Trapasso, F., Shiraishi, T., Alder, H., Mimori, K., Mori, M., and Croce, C. M. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res., 62: 2258-2260, 2002.
13. Yendamuri, S., Kuroki, T., Trapasso, F., Henry, A. C., Dumon, K. R., Huebner, K., Williams, N. N., Kaiser, L. R., and Croce, C. M. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res., 63: 878-881, 2003.
14. Bednarek, A. K., Keck-Waggoner, C. L., Daniel, R. L., Laflin, K. J., Bergsagel, P. L., Kiguchi, K., Brenner, A. J., and Aldaz, C. M. WWOX, the FRA16D gene, behaves asa suppressor of tumor growth. Cancer Res., 61: 8068-8073, 2001.
15. Chang, N. S., Doherty, J., and Ensign, A. JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J. Biol. Chem., 278: 9195-9202, 2003.
16. Iizuka, M., and Smith, M. M. Functional consequences of histone modifications. Curr. Opin. Genet. Dev., 13: 154-160, 2003.
17. Yakicier, M. C., Legoix, P., Vaury, C., Gressin, L., Tubacher, E., Capron, F., Bayer, J., Degott, C., Balabaud, C., and Zucman-Rossi, J. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene, 20: 5232-5238, 2001.
18. Baffa, R., Gomella, L. G., Vecchione, A., Bassi, P., Mimori, K., Sedor, J., Calviello, C. M., Gardiman, M., Minimo, C., Strup, S. E., McCue, P. A., Kovatich, A. J., Pagano, F., Huebner, K., and Croce, C. M. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am. J. Pathol., 156: 419-424, 2000.
19. Baffa, R., Veronese, M. L., Santoro, R., Mandes, B., Palazzo, J. P., Rugge, M., Santoro, E., Croce, C. M., and Huebner, K. Loss of FHIT expression in gastric carcinoma. Cancer Res., 58: 4708-4714, 1998.
20. Lin, P. M., Liu, T. C., Chang, J. G., Chen, T. P., and Lin, S. F. Aberrant FHIT transcripts in acute myeloid leukemia. Br. J. Haematol., 99: 612-617, 1997.
21. Iwai, T., Yokota, S., Nakao, M., Nakazawa, N., Taniwaki, M., Kimura, T., Sonoda, Y., Kaneko, H., Okuda, T., Azuma, H., Oka, T., Takeda, T., Watanabe, A., Kikuta, A., Asami, K., Sekine, I., Matsushita, T., Tsuchiya, T., Mimaya, J., Koizumi, S., Ohta, S., Miyake, M., Takaue, Y., Iwai, A., and Fujimoto, T. Frequent aberration of FHIT gene expression in acute leukemias. Cancer Res., 58: 5182-5187, 1998.
22. Albitar, M., Manshouri, T., Gidel, C., Croce, C., Komblau, S., Pierce, S., and Kantarjian, H. M. Clinical significance of fragile histidine triad gene expression in adult acute lymphoblastic leukemia. Leuk. Res., 25: 859-864, 2001.
23. Hallas, C., Albitar, M., Letofsky, J., Keating, M. J., Huebner, K., and Croce, C. M. Loss of FHIT expression in acute lymphoblastic leukemia. Clin. Cancer Res., 5: 2409-2414, 1999.
24. Kantarjian, H. M., Talpaz, M., O'Brien, S., Manshouri, T., Cortes, J., Giles, F., Rios, M. B., Croce, C. M., and Albitar, M. Significance of FHIT expression in chronic myelogenous leukemia. Clin. Cancer Res., 5: 4059-4064, 1999.
25. Maruyama, R., Toyooka, S., Toyooka, K. O., Virmani, A. K., Zochbauer-Muller, S., Farinas, A. J., Minna, J. D., McConnell, J., Frenkel, E. P., and Gazdar, A. F. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res., 8: 514-519, 2002.
26. Maruyama, R., Toyooka, S., Toyooka, K. O., Harada, K., Virmani, A. K., Zochbauer-Muller, S., Farinas, A. J., Vakar-Lopez, F., Minna, J. D., Sagalowsky, A., Czemiak, B., and Gazdar, A. F. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res., 61: 8659-8663, 2001.
27. Chang, K. W., Kao, S. Y., Tzeng, R. J., Liu, C. J., Cheng, A. J., Yang, S. C., Wong, Y. K., and Lin, S. C. Multiple molecular alterations of FHIT in betel-associated oral carcinoma. J. Pathol., 196: 300-306, 2002.
28. Peters, U. R., Hasse, U., Oppliger, E., Tschan, M., Ong, S. T., Rassool, F. V., Borisch, B., Tobler, A., and Fey, M. F. Aberrant FHIT mRNA transcripts are present in malignant and normal hematopoiesis, but absence of FHIT protein is restricted to leukemia. Oncogene, 18: 79-85, 1999.
29. Carapeti, M., Aguiar, R. C., Sill, H., Goldman, J. M., and Cross, N. C. Aberrant transcripts of the FHIT gene are expressed in normal and leukemic hemopoietic cells. Br. J. Cancer, 78: 601-605, 1998.
30. Drexler, H. G. and Minowada, J. History and classification of human leukemia-lymphoma cell lines. Leuk. Lymphoma, 31: 305-316, 1998.
31. Drexler, H. G., Matsuo, Y., and MacLeod, R. A. F. Continuous hematopoietic cell lines as model systems for leukemia-lymphoma research. Leuk. Res., 24: 881-911, 2000.
32. Maier, J. A., Voulalas, P., Roeder, D., and Maciag, T. Extension of the life-span of human endothelial cells by an interleukin-α antisense oligomer. Science, 249: 1570-1574, 1990.
33. Ausubel, F. M., Brent, R., Kingston, R. E., Moor, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. Current Protocols in Molecular Biology. New York: Wiley-Interscience, 1989.